Approval Agency Reforms In Asia Leave Mark On Drug Pricing – DIA Asia New Drug Development Conference
This article was originally published in PharmAsia News
Executive Summary
Drug development doesn’t happen in a bubble. Speakers at DIA’s Asia New Drug Development Conference in Tokyo urged attendees to consider the impact of unique government pricing mechanisms in the region when bringing a new product to market.
You may also be interested in...
Japanese, Chinese Regulators Step Up Communications To Increase Effectiveness, Speed Up Approval - DIA China Conference
BEIJING - Communication with regulators is essential for clinical development success and increasingly drug companies are engaging with multiple regulators simultaneously along parallel tracks; regulators are responding in some surprising ways that show they are willing to change, leaders from China and Japan told scientists and executives at the China Drug Information Association meeting in Beijing May 18
FCPA In The China Framework Warrants Special Attention
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas Regains Japan Losses With Xtandi Expansion
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.